This federal Project Grant award of $430,375.00 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) supports research by Emory University to investigate neurogenic defects in cellular models of Fragile X Syndrome. The project aims to determine if cyclic AMP signaling is disrupted during early brain development in Fragile X Syndrome and whether targeting the microtubule-associated protein Doublecortin could have therapeutic...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the CFDA program "Extramural Research Programs in the Neurosciences and Neurological Disorders" (93.853), provides $187,500.00 in funding to the University of South Florida to explore the role of the protein Reelin in Fragile X Syndrome (FXS). The research aims to validate a gene therapy approach using an optimized Reelin fragment to restore cognitive deficits in an FXS...
The National Institute of Child Health and Human Development (NICHD) awarded a $267,310 project grant to The Trustees of the University of Pennsylvania under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant, awarded on August 10, 2024, will support a research project to investigate the mechanisms by which the mutation-length CGG short tandem repeat in the FMR1 gene coordinates megabase-scale heterochromatin domains and their inter-chromosomal...
The Washington University Office of Sponsored Research Services Division received a $427,625 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant supports research to unravel the role of satellite glial cells in sensory hypersensitivity in Fragile X Syndrome, a leading genetic cause of autism spectrum disorders. Key activities include: Examining how...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), supports research to understand the molecular mechanisms governing lymphatic dysfunction in a mouse model of neurodevelopmental disorder, specifically Fragile X syndrome (FXS). The $836,125.47 award, effective December 16, 2024 through November 30, 2029, aims to characterize the role of the meningeal lymphatic system in FXS-associated social and...
The University of Illinois was awarded an $872,300 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to define the developmental time course and therapeutic window for sensory circuit impairments in a rat model of Fragile X syndrome. The three-year award beginning April 15, 2023 will support basic research investigating medical solutions for sensory processing deficits observed in those with Fragile X, with the...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $596,937 to the University of Wisconsin System to research the role of the RNA-binding protein FMRP in regulating mitochondrial function and energy metabolism in human neuron development. The 5-year project aims to: 1) investigate the impact of FMRP and its target RACK1 on...
The Department of the Army Medical Command awarded a $1,324,049 Project Grant to the University of Wisconsin-Madison through the Military Medical Research and Development program (CFDA 12.420) to identify neuronal signatures that distinguish Fragile X syndrome (FXS) patients with distinct electroencephalogram (EEG) phenotypes. The four-year award beginning August 1, 2022 will support research to investigate medical solutions for the battlefield by transforming healthcare through innovative...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $443,121.00 to the University of California, Santa Cruz (UCSC) to leverage innovative in situ cryo-electron microscopy (cryo-EM) techniques to study dysregulated protein synthesis, or translation, in an autism spectrum disorder (ASD) model. The key objectives are to: 1) Develop a...
This Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD) under the Research Related to Deafness and Communication Disorders program (CFDA 93.173) will provide $160,000 to Northwestern University to investigate the mechanistic origins of pragmatic language deficits associated with autism spectrum disorder (ASD) and the FMR1 premutation condition. The research aims to characterize the motor-speech skills contributing to pragmatic language...